CEBPZ and acute myeloid leukemia: The occurrence rates of the exon 8 and 17 mutations were 1.5–18.5% [14, 38] and 4–31% [3, 10], respectively, when CBF-AML was regarded as an group, and they were 0–13% [4],[38] and 6–38% [3],[29], respectively, in t(8;21) AML and 3–33% [17, 41] and 2–32%[3, 8], respectively, in inv(16) AML.